|Bid||12.17 x 1300|
|Ask||12.22 x 1400|
|Day's Range||11.17 - 12.36|
|52 Week Range||8.37 - 17.77|
|Beta (5Y Monthly)||1.07|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
It is now my pleasure to turn the call over to Matt McLaughlin, Chief Financial Officer. Good morning and thank you for joining us to review Oxford Immunotec's financial results for the first quarter of 2020. Any statements made during this call that are not statements of historical or current facts are intended to be forward-looking statements pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.
Oxford Immunotec (OXFD) delivered earnings and revenue surprises of -185.71% and -1.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Oxford Immunotec Global (NASDAQ:OXFD) remained unaffected at $11.76 after the company reported Q1 results.Quarterly Results Earnings per share were down 233.33% over the past year to ($0.20), which missed the estimate of ($0.15).Revenue of $13,911,000 less by 5.94% from the same period last year, which beat the estimate of $13,450,000.Outlook Earnings guidance hasn't been issued by the company for now.Q2 revenue expected between $5,000,000 and $6,000,000.How To Listen To The Conference Call Date: May 05, 2020View more earnings on OXFDTime: 10:01 PM ETWebcast URL: https://edge.media-server.com/mmc/p/g5rzprwmPrice Action 52-week high: $17.7752-week low: $8.37Price action over last quarter: down 10.98%Company Overview Oxford Immunotec Global PLC is a diagnostic company. It is focused on developing and commercializing proprietary tests for the management of underserved immune regulated conditions. Its products include T-spot TB, T-spot-CMV, T-spot PRT,T-cell extend etc. The company's research and development activities focus on Chronic infections, Transplantation, Autoimmune and Inflammatory disease, Immune oncology.See more from Benzinga * JELD-WEN Holding: Q1 Earnings Insights * Recap: Crestwood Equity Partners Q1 Earnings * Atkore International: Q2 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Investors can approximate the average market return by buying an index fund. While individual stocks can be big...
Oxford Immunotec (OXFD) delivered earnings and revenue surprises of 45.45% and 4.80%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
Oxford Immunotec Global is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
Oxford Immunotec (OXFD) delivered earnings and revenue surprises of 180.00% and 4.17%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Oxford Immunotec (OXFD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Buying a low-cost index fund will get you the average market return. But if you invest in individual stocks, some are...
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Oxford Immunotec (OXFD) delivered earnings and revenue surprises of 140.00% and 0.76%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Varian (VAR) expects to enhance cancer care with the new collaboration with IAEA, which is likely to drive Varian's core Oncology business.
Wright Medical (WMGI) continues to benefit from strong international sales, new product launches and solid prospects in the global Orthopedic space.